EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis

Jiayuan Qin iD, Hongxia Bi, Guangmin Tang, Xinyao Liu, Junyan Qu, Xiaoju Lv iD, Yanbin Liu iD

Microorganisms · 01.01.2025 · 13 (1) · 55

DOI: 10.3390/microorganisms13010055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microorganisms, online erschienen am 01.01.2025. Verfasst von Jiayuan Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Infectious Diseases, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu 610041, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive mucormycosis (IM) poses a substantial morbidity and mortality burden among immunocompromised patients.

Objectives

We aim to compare the real-world effectiveness and safety of isavuconazole with those of amphotericin B in patients with IM. Patients and methods: In this observational cohort study, we enrolled patients who were diagnosed with IM and treated with either isavuconazole or amphotericin B.

Results

A total of 106 patients met the study criteria. Of these, 47 received isavuconazole, and 59 received amphotericin B as the primary treatment. The two cohorts had similar baseline characteristics, including a history of malignancy, use of immunosuppressants, infection sites, and pathogens. The amphotericin B group demonstrated a significantly greater incidence of renal disorders (p < 0.001) and hypokalemia (p < 0.001) than the isavuconazole group. The proportion of patients who received salvage therapy was greater in the amphotericin B group than in the isavuconazole group (42% vs. 6%, p < 0.001). Eighteen patients in the amphotericin B group discontinued treatment because of adverse events, whereas no patients in the isavuconazole group discontinued treatment because of adverse events. A significant difference in the primary therapeutic response between the isavuconazole and amphotericin B groups was noted (p = 0.013), with a higher treatment failure rate in the amphotericin B group (68% vs. 36%, p = 0.001). However, there were no significant differences in all-cause mortality or mucormycosis-attributable mortality rates between the two groups.

Conclusions

Isavuconazole outperformed amphotericin B as a first-line treatment option for IM in terms of its clinical effectiveness and safety.

Schlagwörter

Stichwörter der Autor:innen

amphotericin Beffectivenessinvasive mucormycosisisavuconazolereal-worldsafety

Autor:innen und Institutionen

  • Center of Infectious Diseases, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu 610041, China.
  • State Key Laboratory of Biotherapy, Division of Infectious Diseases, Chengdu 610041, China.
  • Center for Pathogen Research, West China Hospital, Sichuan University, Chengdu 610041, China.

ORCID-Profile: Jiayuan Qin, Xiaoju Lv, Yanbin Liu

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Qin, J., Bi, H., Tang, G., Liu, X., Qu, J., Lv, X., & Liu, Y. (2025). Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis. Microorganisms, 13(1), 55. https://doi.org/10.3390/microorganisms13010055

Vancouver

Qin J, Bi H, Tang G, Liu X, Qu J, Lv X, et al. Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis. Microorganisms. 2025;13(1):55. doi:10.3390/microorganisms13010055

BibTeX
@article{Qin2025,
  author = {Qin, Jiayuan and Bi, Hongxia and Tang, Guangmin and Liu, Xinyao and Qu, Junyan and Lv, Xiaoju and Liu, Yanbin},
  title = {Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis},
  journal = {Microorganisms},
  year = {2025},
  volume = {13},
  number = {1},
  pages = {55},
  doi = {10.3390/microorganisms13010055}
}
Kostenlos starten →